UNSPSC 51263160: Cicloprolol hydrochloride

This classification denotes the hydrochloride form of a beta-adrenergic blocking agent with the molecular formula C18H29NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1K2ACH4U3R, chemically known as 2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethoxy)phenoxy)-3-((1-methylethyl)amino)- but more generally known as cicloprolol, which bears US NIH Compound Identifier 146294. European Medicines Agency schedules Cicloprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06248MIG.

UNSPSC 51263160 Cicloprolol hydrochloride is a Commodity code that captures pharmaceutical products procured by state and local health agencies. The recent solicitation activity under this code, however, shows a significant mismatch: Seminole County, Florida's IFB 60459723LAS, posted in June 2026, seeks naloxone and safe drug deactivation systems rather than cicloprolol hydrochloride. The code's nominal scope — a specific beta-blocker medication — does not align with the actual procurement being conducted under it. State and local health departments and county public-health entities appear to be the primary issuing bodies using this code classification, though the single available opportunity provides limited visibility into repeat-buyer patterns or broader issuing-body mix.

The geographic footprint visible in recent activity is limited to Florida, where Seminole County released the naloxone and drug-deactivation systems bid with a response deadline of July 26, 2023 (note: this date precedes the current date of October 20, 2026, suggesting the opportunity has closed). The solicitation is an IFB calling for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract includes a two-year initial term with a one-year renewal option, fixed-fee pricing, standard compliance requirements including drug-free workplace certification and E-Verify, and potential FEMA funding with associated federal environmental-compliance obligations. The mismatch between the code's pharmaceutical name and the actual procurement suggests either a tagging error in the state or local procurement system or that this code is used more broadly than its name indicates; either way, the code shows minimal recent relevant activity aligned with its stated commodity scope.